Business Wire

Dole Unveils Integrated Strategy Against Banana Disease

Share

Dole Food Company today shared the company’s most recent update on its efforts to combat Fusarium Tropical Race 4 (TR4), a plant disease that poses an existential threat to bananas, a major staple crop for much of the world.

Since the discovery of TR4 in northern Colombia one year ago, Dole swiftly ramped-up its TR4 response plan, implementing site-specific TR4 prevention activities throughout Latin America in coordination with local authorities and international experts to contain and prevent spread.

A three-year containment program was immediately implemented in 2019 to ensure biosecurity protocols in every Dole banana farm, as well as those of Dole’s independent suppliers. Those protocols build upon best practices implemented in the banana producing countries where the disease has been successfully contained and are continually reviewed and strengthened per site—based upon the farm layout and location—to maximize the effectiveness of the risk-based mitigation plan.

Dole also continues to share these best practices with independent growers and to engage with governments, multi-stakeholder initiatives and industry partners to ensure that our actions are coordinated with the wider response, both in Latin America and globally. These efforts require significant investment and as of now there is no evidence that TR4 has spread from the area in Colombia in which it was initially detected.

“Fortunately to date, the spread of this disease in Latin America has been contained to only the La Guajira region of Colombia, but this issue is not isolated to one region or one banana grower; it affects the entire industry and we must all be vigilant,” stated Patricio Gutiérrez, Director of Innovation R&D, Dole Tropical Products. “Containment alone is not sufficient. We must find ways to move beyond defense and find a sustainable solution to this issue in the long-term.”

Dole is exploring a number of potential resolutions.

One such solution the company is investigating is how to implement safe and approved biological control measures to prevent disease.

Additionally, Dole is working closely with research institutions around the world toward developing a disease resistant banana variety through crop improvement and conventional breeding methods. Since 2016, Dole has participated in a consortium working in partnership with the Honduran Research Foundation (FHIA) on the development of banana varieties that are resistant to TR4. Although developing a new kind of banana through traditional breeding is painstaking work, the research team is making good progress and a number of lines are currently being pot or field tested for TR4 resistance.

More recently, Dole began collaborating with companies working on precision biotechnology as a means to develop TR4 resistant bananas and is also part of the Global Alliance against TR4 led by IICA and Bayer in collaboration with other large banana stakeholders. When and if either these efforts or the other work being done by third parties succeed, Dole intends to be part of the discussion on how to make the solution available to banana growers worldwide.

About Dole Food Company

Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

US Contact: William Goldfield
818-874-4647
william.goldfield@dole.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye